At a glance

ClinicalIndex Comparison Record

N/ACompleted· 35 enrolled

Drug / intervention

Procalcitoninother

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04634188

NCT04634188N/ACompleted

Compare CT.gov

Role and Value of Inflammatory Markers in Brain Tumors : A Case Controlled Study

Universitas Sumatera Utara·observational·Posted Nov 18, 2020·Updated Nov 18, 2020

In Brief

An observational study evaluating Procalcitonin for Brain Tumor. Completed, enrolled 35 participants across 1 site.

Detailed Summary

This study is a case controlled analytical study that analyzes the relationship between levels of inflammatory markers with the type of brain tumor. Samples of 35 people were then categorized according to the variables above and analyzing to measure its significance

Study Details

Study Typeobservational

Allocation--

Masking--

Primary Purpose--

ConditionsBrain Tumor

CountriesIndonesia

Collaborators--

Timeline

N/ACompletedFinished

2020202120222023202420252026

Enrollment StartJan 2020

Primary CompletionSep 2020

Study CompletionOct 2020

First PostedNov 2020

TodayJul 2026

First PostedNov 18, 2020

Enrollment StartJan 1, 2020

Primary CompletionSep 1, 2020

Study CompletionOct 1, 2020

TodayJul 2, 2026

Enrollment to primary: 8 monthsPosted 5.6 years ago

Interventions

Procalcitoninother

Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically